Research programme: equine encephalitis virus vaccine - Maxygen

Drug Profile

Research programme: equine encephalitis virus vaccine - Maxygen

Alternative Names: Eastern equine encephalitis virus vaccine - Maxygen; Maxy 829; Maxy-EE; Vaccines against encephalitis alphaviruses - Maxygen; Venezuelan equine encephalitis virus vaccine - Maxygen; Western equine encephalitis virus vaccine - Maxygen

Latest Information Update: 10 Jun 2013

Price : $50

At a glance

  • Originator Maxygen
  • Developer Maxygen; United States Army Medical Research Institute of Infectious Diseases
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Encephalitis virus infections

Most Recent Events

  • 10 Jun 2013 Discontinued - Preclinical for Encephalitis virus infections in USA (Parenteral)
  • 18 Sep 2008 Preclinical development is ongoing
  • 18 Sep 2008 This equine encephalitis vaccine programme is available for licensing (http://www.maxygen.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top